Eugènia Almacellas1,2, Joffrey Pelletier2, Charles Day3,4, Santiago Ambrosio5, Albert Tauler1,2, Caroline Mauvezin2. 1. Department of Biochemistry and Physiology, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain. 2. Metabolism and Cancer Laboratory, Molecular Mechanisms and Experimental Therapy in Oncology Program (Oncobell, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, L'Hospitalet de Llobregat, Spain. 3. Hormel Institute, University of Minnesota, Austin, MN, USA. 4. Neuro-Oncology Program, Mayo Clinic, Rochester, MN, USA. 5. Department of Physiological Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Abstract
Lysosomes, as primary degradative organelles, are the endpoint of different converging pathways, including macroautophagy. To date, lysosome degradative function has been mainly studied in interphase cells, while their role during mitosis remains controversial. Mitosis dictates the faithful transmission of genetic material among generations, and perturbations of mitotic division lead to chromosomal instability, a hallmark of cancer. Heretofore, correct mitotic progression relies on the orchestrated degradation of mitotic factors, which was mainly attributed to ubiquitin-triggered proteasome-dependent degradation. Here, we show that mitotic transition also relies on lysosome-dependent degradation, as impairment of lysosomes increases mitotic timing and leads to mitotic errors, thus promoting chromosomal instability. Furthermore, we identified several putative lysosomal targets in mitotic cells. Among them, WAPL, a cohesin regulatory protein, emerged as a novel SQSTM1-interacting protein for targeted lysosomal degradation. Finally, we characterized an atypical nuclear phenotype, the toroidal nucleus, as a novel biomarker for genotoxic screenings. Our results establish lysosome-dependent degradation as an essential event to prevent chromosomal instability.Abbreviations: 3D: three-dimensional; APC/C: anaphase-promoting complex; ARL8B: ADP ribosylation factor like GTPase 8B; ATG: autophagy-related; BORC: BLOC-one-related complex; CDK: cyclin-dependent kinase; CENPE: centromere protein E; CIN: chromosomal instability; ConcA: concanamycin A; CQ: chloroquine; DAPI: 4,6-diamidino-2-penylinole; FTI: farnesyltransferase inhibitors; GFP: green fluorescent protein; H2B: histone 2B; KIF: kinesin family member; LAMP2: lysosomal associated membrane protein 2; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MEF: mouse embryonic fibroblast; MTOR: mechanistic target of rapamycin kinase; PDS5B: PDS5 cohesin associated factor B; SAC: spindle assembly checkpoint; PLEKHM2: pleckstrin homology and RUN domain containing M2; SQSTM1: sequestosome 1; TEM: transmission electron microscopy; ULK1: unc-51 like autophagy activating kinase 1; UPS: ubiquitin-proteasome system; v-ATPase: vacuolar-type H+-translocating ATPase; WAPL: WAPL cohesion release factor.
Lysosomes, as primary degradative organelles, are the endpoint of different converging pathways, including macroautophagy. To date, lysosome degradative function has been mainly studied in interphase cells, while their role during mitosis remains controversial. Mitosis dictates the faithful transmission of genetic material among generations, and perturbations of mitotic division lead to chromosomal instability, a hallmark of cancer. Heretofore, correct mitotic progression relies on the orchestrated degradation of mitotic factors, which was mainly attributed to ubiquitin-triggered proteasome-dependent degradation. Here, we show that mitotic transition also relies on lysosome-dependent degradation, as impairment of lysosomes increases mitotic timing and leads to mitotic errors, thus promoting chromosomal instability. Furthermore, we identified several putative lysosomal targets in mitotic cells. Among them, WAPL, a cohesin regulatory protein, emerged as a novel SQSTM1-interacting protein for targeted lysosomal degradation. Finally, we characterized an atypical nuclear phenotype, the toroidal nucleus, as a novel biomarker for genotoxic screenings. Our results establish lysosome-dependent degradation as an essential event to prevent chromosomal instability.Abbreviations: 3D: three-dimensional; APC/C: anaphase-promoting complex; ARL8B: ADP ribosylation factor like GTPase 8B; ATG: autophagy-related; BORC: BLOC-one-related complex; CDK: cyclin-dependent kinase; CENPE: centromere protein E; CIN: chromosomal instability; ConcA: concanamycin A; CQ: chloroquine; DAPI: 4,6-diamidino-2-penylinole; FTI: farnesyltransferase inhibitors; GFP: green fluorescent protein; H2B: histone 2B; KIF: kinesin family member; LAMP2: lysosomal associated membrane protein 2; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MEF: mouse embryonic fibroblast; MTOR: mechanistic target of rapamycin kinase; PDS5B: PDS5 cohesin associated factor B; SAC: spindle assembly checkpoint; PLEKHM2: pleckstrin homology and RUN domain containing M2; SQSTM1: sequestosome 1; TEM: transmission electron microscopy; ULK1: unc-51 like autophagy activating kinase 1; UPS: ubiquitin-proteasome system; v-ATPase: vacuolar-type H+-translocating ATPase; WAPL: WAPL cohesion release factor.
Chromosomal instability (CIN) is defined as an abnormal gain or loss of chromosomes during cell division [1] and positively correlates with poor cancer patient prognosis [2]. The mechanisms underlying CIN remain poorly characterized but reflect abnormalities in kinetochore-microtubule attachment, sister chromatids cohesion, centrosome duplication, telomeres or the spindle assembly checkpoint (SAC) [3].To maintain genome integrity, the cell cycle must be tightly coordinated to ensure the faithful transmission of hereditary information between generations. Cells spend more than 90% of their time in interphase, and interphase length correlates with total length of the cell cycle [4]. In contrast, mitosis time is extremely short, remarkably constant and uncoupled from the variability in other phases. Mitosis is the process by which a cell properly divides its genetic material and consists of five active phases from prophase to telophase. The major mitotic checkpoint known as SAC comprises the metaphase-to-anaphase transition, separating mitotic entry and exit. Coordination of the mitotic regulatory network relies on hierarchal phosphorylation cascades driven by cyclin-dependent kinases (CDKs) [5,6] and the ubiquitin-proteasome system (UPS) under the control of the anaphase-promoting complex (APC/C) [7,8]. During mitosis, known degradative functions are mainly restricted to UPS, specialized in ubiquitin-triggered protein degradation and presumably faster than lysosome-dependent degradation.Lysosomes are acidic cytosolic vesicles responsible to enzymatically degrade all types of biological material. During macroautophagy/autophagy, double-membrane vesicles (autophagosomes) engulf cytosolic material, converge and fuse with lysosomes. The lysosomal proton pump vacuolar-type H+-translocating ATPase (v-ATPase) drives lumen acidification while the BLOC-one-related complex (BORC)-associated proteins, including KIF5B motor protein, is the main driver of anterograde lysosomal transport and also contributes to autophagosome-lysosome fusion [9-11]. Autophagy-dependent degradation of cargos can either be nonselective (bulk) or targeted (selective). Receptor proteins, such as SQSTM1/p62 (sequestosome 1), regulate selective autophagy [12,13]. Being cytosolic vesicles, research on autophagy and lysosomes has mainly focused on interphase cells. As cells undergo mitosis, dramatic structural rearrangements of organelles occur [14-16]. Recent studies present controversial observations about the function of lysosomes and autophagy in mitosis. Some of them claim that autophagy signaling is shut-down at mitotic entry, that autophagic structures are barely detected in dividing cells and that proteasome-dependent WIPI2 degradation upon mitotic induction suppresses autophagic flux [17-20]. In contrast, lysosomal-dependent degradation has been implicated in CCNA2 (cyclin A2) proteolysis during mitosis [21] and mitophagy has been shown to remain active in prophase [22,23]. ULK1 (unc-51 like autophagy activating kinase 1), an autophagy initiator protein, was shown to drive SAC recruitment to kinetochores through MAD1 L1 (mitotic arrest deficient 1 like 1) phosphorylation [24]. Furthermore, selective autophagic degradation of centriolar satellites was recently demonstrated to support correct karyokinesis [25,26]. Loss of BECN1 (beclin 1), another key autophagic protein, induced gene amplification and consequent aneuploidy [27]. Better understanding of the regulatory mechanisms driving mitotic transitions is crucial to prevent CIN and develop novel cancer treatment strategies.Here, we show that correct mitotic progression does not rely only on UPS-dependent degradation. Dissecting the mitotic progression, we define a novel function of selective autophagy and lysosome-dependent degradation specifically in dividing cells and identify new mitotic lysosomal substrates. Furthermore, impairment of lysosome function during cell division triggers chromosome mis-segregation and induces a striking nuclear phenotype in progeny, the toroidal nucleus, which provides a new tool for genotoxicity tests.
Results
Lysosomes and autophagic vesicles are present and active during cell division
To investigate the presence of lysosomes in mitotic subphases, LAMP2-positive vesicles and DAPI-stained DNA were analyzed by immunofluorescence. Here, we showed that lysosomes are present and dynamic in all mitotic subphases (Figure 1A and Video 1). Morphological analysis of mitotic lysosomes indicated that lysosomes decreased in number while increased in size from prophase to telophase, when they started recovering their interphase-like morphology (Figure 1A–C and Video 1). In addition, lysosome distribution changed once cells proceeded into cell division. Mitotic lysosomes surrounded the chromosomes in prophase and moved to the edges of chromosomes during anaphase/telophase until chromosomes decondensed (Figure 1D). To analyze whether mitotic lysosomes maintain their degradation capacity during cell division, we stained live U2OS cells stably expressing Histone 2B-GFP (H2B-GFP U2OS) with LysoSensor for acidic organelle detection and Magic Red for lysosomal CTSB (cathepsin B) activation. Colocalization between LysoSensor and Magic Red supported the presence of functional lysosomes in dividing cells (Figure 1E and S1A).
Figure 1.
Autophagic flux and lysosome-dependent degradation are active in dividing cells. (A) Representative single focal plane (1Z) confocal images of U2OS cells undergoing mitosis labeled with lysosomal marker LAMP2 (green). Interphase cell and distinct mitotic subphases are detectable with DNA staining with DAPI (blue). Scale bar: 10 µm. (B-C) Quantification of lysosome number (B) and size (C) per cell in interphase compared to each mitotic subphase. Error bars represent S.D. of n ≥ 10 cells. (D) Upper panel: Analysis of the distribution of lysosomes (green) and DNA (blue) in interphase and for each mitotic subphase using Radial Profile Angle ImageJ plugin. A radius of 20 μm was maintained constant for the analysis. Lower panel: representative image of a cell in each analyzed phase. (E) Representative single focal plane confocal images of U2OS H2B-GFP stable cells in interphase or undergoing mitosis were stained with LysoSensor (green – arbitrary color) for lysosomes detection, Magic Red (red) for active CTSB, H2B-GFP (blue – arbitrary color) for DNA staining. Scale bar: 10 µm. (F) Representative single focal plane (1Z) confocal images of U2OS LC3-Tandem cells in interphase or undergoing mitosis. Presence of yellow and red vesicles indicates autophagosomes and autolysosomes, respectively. Nuclei were stained with DAPI for DNA detection. Scale bar: 10 µm. (G) U2OS cells stably expressing LC3-tandem construct were treated or not with ConcA (10 nM) or CQ (10 µM) for 24 h. Quantification of red (acidified) and yellow (non-acidified) autophagic vesicles in interphase and mitotic cells under the indicated conditions was performed. (H) Analysis of autophagic flux by western blot detection upon synchronization-release protocol (T0: G2 population; T8: G1 population after mitosis). Autophagic proteins SQSTM1 and LC3 were analyzed and ACTB/β-actin protein level was used as loading control. (I) Representative TEM images of mitotic cells. Green asterisks indicate autophagic vesicles, blue asterisks mark lysosomes and yellow asterisks point out mitochondria. Scale bars: as indicated. Panels B, C, and G, statistical significance between interphase and mitotic subphases is represented as: * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant
As we found that lysosomes are present and active in mitosis, we analyzed the autophagic flux during cell division. To this end, we detected and quantified acidified and non-acidified autophagic vesicles using MAP1LC3/LC3-tandem (RFP-GFP-LC3) reporter in mitotic cells treated or not with concanamycin A (ConcA) or chloroquine (CQ) (Figure 1F, 1G and S1B). The presence of acidified autophagic vesicles (red-only vesicles) in control conditions confirmed that lysosome acidification takes place while cells progress through mitosis. Inhibition of autophagic flux by ConcA or CQ was supported by the significant increase of non-acidified autophagic vesicles throughout the mitotic subphases (Figure 1F, 1G and S1B). Next, we analyzed the expression of SQSTM1 and the lipidated form of LC3 (LC3-II) in mitosis after inhibition of lysosomal acidification with ConcA. Established synchronization protocols, such as serum starvation or double-thymidine block, were insufficient to efficiently synchronize U2OS cells in G2. Therefore, based on the ability of CDK1-specific inhibitor RO3306 to reversibly block cells in G2, we established a synchronization-release protocol to obtain enriched mitotic population (Fig. S1C). After synchronization, cells released with ConcA treatment for 8 h showed specific accumulation of LC3-II and SQSTM1 (Figure 1H and S1D). Time-course assay after cell synchronization and release demonstrated that both autophagic proteins gradually accumulated during mitosis transition upon acidification blockade (Fig. S1E and S1F). Subsequently, the upstream regulator of autophagy initiation, mechanistic target of rapamycin kinase complex 1 (MTORC1), was analyzed (Fig. S1G-J). Interestingly, MTORC1 activity, measured by the phosphorylation of RPS6KB1 and RPS6, increased in control cells at G1 reentrance while cells treated with ConcA displayed lower MTORC1 activity (Fig. S1G). Furthermore, analysis of MTORC1 status in mitotic cells compared to interphase cells, demonstrated that MTORC1 activity decreased, independently of ConcA treatment (Fig. S1H). Complementary immunofluorescence analysis showed a decreased recruitment of MTOR to the lysosomes upon mitotic entry, which was slowly recovered after cells entered mitotic exit (Fig. S1I and S1J). Together, our results suggested that MTORC1 lysosomal translocation also correlates with its activity during mitosis.The presence of autophagic vesicles in dividing cells was corroborated by immunofluorescence analysis of both endogenous LC3 and SQSTM1 (Fig. S1K). Indeed, the number and the size of LC3-positive vesicles was significantly increased upon CQ treatment in interphase as well as in mitotic entry and mitotic exit, confirming an active autophagic flux in mitosis (Fig. S1K and S1L). Finally, double-membrane vesicles (autophagosomes), as well as dense single-membrane vesicles (autolysosomes/lysosomes), were detected by transmission electron microscopy (TEM) in mitotic cells (Figure 1I). Collectively, our results demonstrated that both autophagic vesicles and functional lysosomes are present and active in mitotic cells.Autophagic flux and lysosome-dependent degradation are active in dividing cells. (A) Representative single focal plane (1Z) confocal images of U2OS cells undergoing mitosis labeled with lysosomal marker LAMP2 (green). Interphase cell and distinct mitotic subphases are detectable with DNA staining with DAPI (blue). Scale bar: 10 µm. (B-C) Quantification of lysosome number (B) and size (C) per cell in interphase compared to each mitotic subphase. Error bars represent S.D. of n ≥ 10 cells. (D) Upper panel: Analysis of the distribution of lysosomes (green) and DNA (blue) in interphase and for each mitotic subphase using Radial Profile Angle ImageJ plugin. A radius of 20 μm was maintained constant for the analysis. Lower panel: representative image of a cell in each analyzed phase. (E) Representative single focal plane confocal images of U2OS H2B-GFP stable cells in interphase or undergoing mitosis were stained with LysoSensor (green – arbitrary color) for lysosomes detection, Magic Red (red) for active CTSB, H2B-GFP (blue – arbitrary color) for DNA staining. Scale bar: 10 µm. (F) Representative single focal plane (1Z) confocal images of U2OS LC3-Tandem cells in interphase or undergoing mitosis. Presence of yellow and red vesicles indicates autophagosomes and autolysosomes, respectively. Nuclei were stained with DAPI for DNA detection. Scale bar: 10 µm. (G) U2OS cells stably expressing LC3-tandem construct were treated or not with ConcA (10 nM) or CQ (10 µM) for 24 h. Quantification of red (acidified) and yellow (non-acidified) autophagic vesicles in interphase and mitotic cells under the indicated conditions was performed. (H) Analysis of autophagic flux by western blot detection upon synchronization-release protocol (T0: G2 population; T8: G1 population after mitosis). Autophagic proteins SQSTM1 and LC3 were analyzed and ACTB/β-actin protein level was used as loading control. (I) Representative TEM images of mitotic cells. Green asterisks indicate autophagic vesicles, blue asterisks mark lysosomes and yellow asterisks point out mitochondria. Scale bars: as indicated. Panels B, C, and G, statistical significance between interphase and mitotic subphases is represented as: * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant
Lysosome acidification capacity and trafficking maintain correct mitotic progression
To investigate the role of lysosomes in cell division, we studied mitotic cells with impaired lysosomes either by inhibiting their degradative capacity or their intracellular trafficking. Impairment of lysosome acidification by the v-ATPase inhibitor ConcA led to an increase in mitotic lysosome size, according to a defective degradation capacity, without significantly affecting their number or LAMP2 protein levels (Figure 2A, 2D, 2E and S2A). Next, we assessed the effect of the BORC-associated motor protein KIF5B depletion on lysosome morphology, number and distribution in mitotic cells (Figure 2B–E, S2B and S2C). In both interphase and mitotic cells, KIF5B depletion induced a reduction in the lysosomal number without dramatically affecting their size (Figure 2B–D). The distribution of lysosomes was strongly affected in cells depleted for KIF5B in interphase (Figure 2D, 2E), as previously reported [11,28]. Moreover, analysis of the distribution of lysosomes in the different mitotic subphases showed a change in the localization of lysosomes induced by KIF5B depletion (Figure 2E). Indeed, KIF5B-depleted cells lysosomes were closer to the DNA in metaphase cells compared to control cells, as shown by an increase in proximal lysosomes and a decrease in distant lysosomes (Figure 2E, S2D and S2E). In anaphase, an accumulation of lysosomes between the segregated chromosomes occurred upon KIF5B depletion, shown by an increase in proximal lysosomes versus distant lysosomes (Figure 2E, S2D and S2E). These results suggest the implication of this kinesin on the appropriate distribution of lysosomes during mitosis.
Figure 2.
Lysosome impairment delays mitotic progression and leads to chromosomal instability. (A-B) U2OS cells were treated with ConcA 10 nM for 24 h (A) or transiently transfected with silencing RNA against KIF5B (siKIF5B) (B). Single plane confocal images show LAMP2-positive lysosomes (green) detected by immunofluorescence in cells undergoing mitosis. DNA is labeled with DAPI (blue). Scale bars: 10 µm. (C-D) Comparison of the number of lysosomes per cell (C) or average lysosome size (D) in interphase and each mitotic subphases in control, ConcA-treated or KIF5B-depleted cells. Line represents the mean and error bars correspond to 5–95 percentiles. n ≥ 10 images per condition. (E) Intracellular distribution of lysosomes (proximal and distant) in interphase and in each mitotic subphases in control and KIF5B-depleted cells. n ≥ 10 images per condition. (F) H2B-GFP U2OS cells were subjected to time-lapse imaging for 24 h every 6 min 33 s. Single focal plane of representative images of control cells, cells treated with ConcA 10 nM or depleted for KIF5B (siKIF5B) for 48 h undergoing mitosis are shown. H2B-GFP is depicted in grayscale (arbitrary color). Scale bars: 5 µm. (G) Quantification of mitotic timing of the indicated experimental conditions was performed from prophase (chromosomes condensation) to telophase (chromosomes decondensation). Error bars represent 5–95 percentiles of n ≥ 90 mitosis. (H) Representative images of misaligned metaphase plate and chromosome bridges. Scale bar: 5 µm. (I-J) U2OS cells were synchronized at late G2 phase and released with or without ConcA for 1 h to analyze chromosome misalignment compared to total metaphase (I) or 3 h for chromosomal bridges quantification compared to total anaphases (J). DAPI staining was used for DNA detection. Error bars represent S.D. of n = 3 independent experiments (> 200 cells). (K-L) U2OS cells depleted for KIF5B (siKIF5B) or transfected with siRNA control (siNT) were synchronized and released for 1 h to determine the percentage of chromosome misalignment (K) or 3 h for chromosome bridges (L) relative to the total number of cells undergoing metaphase or anaphase, respectively. Error bars represent S.D. of n = 3 experiments (> 150 cells). In panels C-E, G and I-L, statistical significance is represented as: * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant
Mitotic timing is strictly regulated and remarkably constant among different cell types and species [4], taking approximately 1 h in normal mitosis. Thus, after identifying active lysosomes in dividing cells, the direct implication of lysosomes in mitotic progression was tested. To this end, we used live-imaging to analyze H2B-GFP U2OS cells treated or not with ConcA or KIF5B-depleted and analyzed the mitotic timing from prophase (chromosome condensation) to telophase (chromosome decondensation). Mitosis was 22% slower in ConcA-treated cells compared to control, and KIF5B depletion delayed mitotic progression to the same extent (Figure 2F, 2G and Videos 2–4). Combination of ConcA-treatment with KIF5B knockdown increased the average mitotic duration by 45% versus control (Figure 2F and 2G). In all, integrity of both lysosome transport and functionality is key for preserving mitotic schedule. To precisely characterize the involvement of lysosomes in mitotic progression, we separately analyzed the timing of mitotic entry (prophase to metaphase) and exit (metaphase to telophase). Interestingly, both episodes were delayed by treatments that impaired lysosomes. Consistently, the additive effect was reflected in both mitotic entry and exit (Fig. S2F).One of the main causes of mitotic delay is the accumulation of mitotic errors such as misaligned chromosomes at metaphase plate or chromosome bridges appearing during chromosome segregation in anaphase [29] (Figure 2H). Thus, we next quantified the acquirement of mitotic errors in synchronized cells released with or without ConcA. Our results demonstrated that lysosome acidification blockade significantly induces the accumulation of misaligned chromosomes and chromosome bridges (Figure 2I, 2J). In parallel, we tested whether, beyond acidification, the protective role of lysosomes against mitotic errors also relies on trafficking. Depletion of the motor protein KIF5B significantly induced mitotic errors (Figure 2K, 2L). To corroborate that this effect was specific of lysosomal trafficking, other BORC-associated proteins were tested. To this end, ARL8B (ADP ribosylation factor like GTPase 8B) and PLEKHM2 (pleckstrin homology and RUN domain containing M2) were depleted, and mitotic errors were analyzed. Consistent with a role of lysosomal trafficking in mitosis progression, both chromosome misalignment and chromosomal bridge were increased upon ARL8B and PLEKHM2 depletion (Fig. S2G-I). Thus, active lysosomes are important organelles to ensure correct mitosis progression and limit CIN signature.Lysosome impairment delays mitotic progression and leads to chromosomal instability. (A-B) U2OS cells were treated with ConcA 10 nM for 24 h (A) or transiently transfected with silencing RNA against KIF5B (siKIF5B) (B). Single plane confocal images show LAMP2-positive lysosomes (green) detected by immunofluorescence in cells undergoing mitosis. DNA is labeled with DAPI (blue). Scale bars: 10 µm. (C-D) Comparison of the number of lysosomes per cell (C) or average lysosome size (D) in interphase and each mitotic subphases in control, ConcA-treated or KIF5B-depleted cells. Line represents the mean and error bars correspond to 5–95 percentiles. n ≥ 10 images per condition. (E) Intracellular distribution of lysosomes (proximal and distant) in interphase and in each mitotic subphases in control and KIF5B-depleted cells. n ≥ 10 images per condition. (F) H2B-GFP U2OS cells were subjected to time-lapse imaging for 24 h every 6 min 33 s. Single focal plane of representative images of control cells, cells treated with ConcA 10 nM or depleted for KIF5B (siKIF5B) for 48 h undergoing mitosis are shown. H2B-GFP is depicted in grayscale (arbitrary color). Scale bars: 5 µm. (G) Quantification of mitotic timing of the indicated experimental conditions was performed from prophase (chromosomes condensation) to telophase (chromosomes decondensation). Error bars represent 5–95 percentiles of n ≥ 90 mitosis. (H) Representative images of misaligned metaphase plate and chromosome bridges. Scale bar: 5 µm. (I-J) U2OS cells were synchronized at late G2 phase and released with or without ConcA for 1 h to analyze chromosome misalignment compared to total metaphase (I) or 3 h for chromosomal bridges quantification compared to total anaphases (J). DAPI staining was used for DNA detection. Error bars represent S.D. of n = 3 independent experiments (> 200 cells). (K-L) U2OS cells depleted for KIF5B (siKIF5B) or transfected with siRNA control (siNT) were synchronized and released for 1 h to determine the percentage of chromosome misalignment (K) or 3 h for chromosome bridges (L) relative to the total number of cells undergoing metaphase or anaphase, respectively. Error bars represent S.D. of n = 3 experiments (> 150 cells). In panels C-E, G and I-L, statistical significance is represented as: * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant
Mitotic errors induced by lysosome impairment correlate with an abnormal nuclear phenotype: the toroidal nucleus
Defective mitotic progression generated a robust and striking nuclear phenotype in interphase cells. Precisely, we observed a DAPI-stained nucleus with a hole devoid of chromatin (Figure 3A). To understand how this structure was originated, we followed the DNA reorganization during mitosis by live-imaging using H2B-GFP U2OS cells. Our results showed that this unconventional nuclear phenotype forms upon mitosis, being detectable in at least one of the daughter cells once chromosomes decondensed (Figure 3B and Video 5). To assure that this structure does not correspond to an enlarged nucleolus [30], immunofluorescence analysis was performed and results showed that none of the tested nucleolar markers (NCL [nucleolin], FBL [fibrillarin] and UBTF [upstream binding transcription factor]) co-stained with the DAPI-free area (Figure 3C and S3A). To resolve whether this section is nuclear or cytosolic, we imaged the nuclear envelope by immunofluorescence using LMNB1 (lamin B1) and nuclear pore complex (NPC) antibodies (Figure 3D and S3B). Interestingly, the nuclear envelope was correctly formed around the DNA. Further immunofluorescence analysis showed that cytoskeleton filaments such as Phalloidin-stained actin fibers and microtubules, as well as LAMP2-positive lysosomes or LC3-SQSTM1-positive autophagosomes, were present within the void at the center of the nuclei (Figure 3E, S3C and S3D). To discard a nuclear invagination and/or an artifact, three-dimensional (3D) reconstruction of high-quality images using IMARIS software resulted in the characterization of a donut-like shaped structure that we refer to as a “toroidal nucleus” (Figure 3F and Video 6). Ultrastructure analysis of these toroidal nuclei by TEM confirmed that cytosolic material, including autophagic vesicles and lysosomes, were present within the hole (Figure 3G).
Figure 3.
Toroidal nucleus is a novel biomarker for chromosomal instability in interphase cells. (A) Representative image of toroidal nucleus. U2OS cells were fixed and stained with DAPI for DNA detection. Scale bar: 5 µm. (B) Live imaging of H2B-GFP U2OS cells undergoing cell cycle for 16 h every 93 s. Mosaic of single focal plane images indicate aberrant nucleus formation upon cell division. Scale bar: 10 µm. (C-E) U2OS cells were fixed and immunofluorescence was performed using NCL (nucleolin) antibody for nucleolus detection (C), LMNB1 (lamin B1) antibody for nuclear envelope staining (D) or LAMP2 antibody to mark lysosomes (E) and DAPI for DNA labeling. Scale bar: 5 µm. (F) 3D reconstruction using IMARIS software was performed from confocal images stack of toroidal nucleus (Z every 0.1 µm for 11 µm). Blue corresponds to DAPI-stained nucleus and yellow dots mark LAMP2-positive lysosomes. (G) U2OS cells were treated with ConcA for 24 h, fixed and prepared for TEM. Images show toroidal nucleus surrounded by the nuclear envelope. Abbreviations: NE: nuclear envelope, N: nucleus, Cyt: cytosol, AV: autophagic vesicles. Scale bars: as indicated. (H) Analysis of live imaging experiment of cycling H2B-GFP U2OS cells for 24 h every 9 min. The number of mitotic cells with detectable mitotic errors (misaligned chromosomes or chromosomal bridges) and toroidal nuclei per field were quantified. Linear regression was analyzed and Pearson’s coefficient (R) was calculated. (I) Analysis of the percentage of toroidal nucleus formed upon non-apparent mitotic error or after mitotic errors. Error bars represent S.D. of n = 295 mitosis. (J) U2OS cells were depleted for KIF11 for 48 h using silencing RNA or treated with monastrol 100 µM for 24 h. Quantification of toroidal nuclei was performed by detection of DAPI-stained nuclei. Error bars represent S.D. of n > 3 experiments (10 fields/experiment). (K) Samples from panel J were processed by western blot and KIF11 protein levels were analyzed for knockdown efficiency. ACTB was used as a loading control. (L) Table summarizing a screen for toroidal nuclei through various cell lines. Percentage of toroidal nuclei was analyzed in basal population and upon ConcA or monastrol treatments. (M) Representative images of toroidal nuclei in screened cell lines from panel K. Scale bar: 5 µm. Panels I and J statistical significance is represented as: * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant
This phenotype was once reported as donut-shaped nucleus [31]. The authors proposed that farnesyltransferase inhibitors (FTI) induce the formation of toroidal nuclei by causing a PCNT (pericentrin)-related centrosome separation defect in HeLa cells. Thus, we tested whether FTI induced the formation of toroidal nuclei in our model. After confirming the increase of toroidal nuclei by FTI in HeLa cells (Fig. S3E, left), we demonstrated that U2OS cells did not respond to FTI (Fig. S3E, right). This contrasts with our results that impairment of lysosome acidification by ConcA, which significantly increased the percentage of toroidal nuclei in both cell types (Fig. S3E). To verify that FTI does not stimulate toroidal nuclei formation with different kinetics in U2OS, we analyzed U2OS cells treated for 24 h, 48 h and 72 h with FTI or ConcA. While ConcA gradually induced a robust increase of toroidal nuclei with time, FTI did not (Fig. S3F).Next, we analyzed whether inhibition of lysosome acidification by ConcA or CQ induced the inhibition of farnesylation of LMNA (lamin A/C). Neither ConcA nor CQ impeded LMNA farnesylation like FTI (Fig. S3G). Based on these results, we hypothesized that the formation of toroidal nuclei is not due to the inhibition of farnesylation per se, but to a defect in mitotic progression regardless of its inducer. As toroidal nuclei were formed following karyokinesis, we examined by live imaging a putative link between the occurrence of mitotic errors and the formation of toroidal nuclei. The results showed a linear correlation between detectable mitotic errors and toroidal nucleus generation with a Pearson’s correlation coefficient of 0.806 (Figure 3H). Indeed, single-cell analysis demonstrated that more than 80% of cells with toroidal nuclei resulted from cells undergoing apparent defective mitosis (Figure 3I). Based on this, we next investigated the repercussion of mitotic stresses on generating toroidal nuclei. To this end, we depleted cells of KIF11, a kinesin required for bipolar spindle establishment [32], and analyzed the formation of toroidal nuclei. Disruption of KIF11 by small interfering RNA (siKIF11) or by the KIF11-specific inhibitor monastrol induced a significant increase in toroidal nucleus frequency (Figure 3J and 3K) without dramatically affecting lysosome morphology and localization (Fig. S3H).Depletion of other kinesins implicated in chromosome segregation, such as siKIF2C/MCAK (kinesin family member 2 C) [33] or siCENPE (centromere protein E) [34] produced a 3.3- and 3.8-fold increase of toroidal nucleus population, respectively (Fig. S3I). In all conditions, siRNA efficiency was validated, and lysosomes morphology or distribution were not apparently perturbed (Fig. S3J and S3K). Furthermore, cells treated with nocodazole, a microtubule de-polymerizing agent, showed a 4.5-fold increased prevalence of toroidal nuclei accompanied by the expected lysosomal collapse (Fig. S3I and S3K). We next investigated whether this phenotype is a consequence of impaired nuclear envelope reformation. Live imaging of H2B-GFP U2OS cells stably expressing mCherry-LMNA, indicated that the reformation of the nuclear envelope preceded the formation of toroidal nuclei (Fig. S3L and Video 7). This nuclear phenotype is versatile in terms of size, nuclear localization and morphology (Fig. S3M i-iv). Furthermore, the nucleus could contain more than one void (Fig. S3M v, viii) and be accompanied by a micronucleus (Fig. S3M vi). After mitosis, one or both daughter cells could harbor this phenotype (Fig. S3M vii-viii).We investigated whether toroidal nucleus was a common feature or specific to U2OS cells. To this end, we screened a panel of cell lines. Toroidal nuclei were detected under the tested conditions in more than 80% of cell lines assessed (Figure 3L). Among them, non-transformed human skin fibroblast (HFF) and embryonic mouse fibroblasts (MEF), as well as cancer cells from lung (A549), cervix (HeLa), colon carcinoma (HCT116 and LoVo) or diffuse intrinsic pontine glioma (SU-DIPG-XVII, MC-PED17 and SF-8628) [35-38]. However, we could not detect toroidal nucleus in RKO, MCF7 or HEK293 T cell lines neither in basal population nor under ConcA or monastrol treatment. Interestingly, the detection of toroidal nuclei in all the other cell lines was evident (compare Figure 3M and S3N), but their sensitivity to induce this nuclear phenotype under the applied treatments varied (Figure 3L). Importantly, most cell lines responded to ConcA-induced blockade of lysosome acidification and to direct mitotic impairment by monastrol as observed by the increased population of toroidal nuclei (Figure 3L and 3M). Thus, toroidal nuclei emerge as a good read-out for mitotic errors in interphase cells.Toroidal nucleus is a novel biomarker for chromosomal instability in interphase cells. (A) Representative image of toroidal nucleus. U2OS cells were fixed and stained with DAPI for DNA detection. Scale bar: 5 µm. (B) Live imaging of H2B-GFP U2OS cells undergoing cell cycle for 16 h every 93 s. Mosaic of single focal plane images indicate aberrant nucleus formation upon cell division. Scale bar: 10 µm. (C-E) U2OS cells were fixed and immunofluorescence was performed using NCL (nucleolin) antibody for nucleolus detection (C), LMNB1 (lamin B1) antibody for nuclear envelope staining (D) or LAMP2 antibody to mark lysosomes (E) and DAPI for DNA labeling. Scale bar: 5 µm. (F) 3D reconstruction using IMARIS software was performed from confocal images stack of toroidal nucleus (Z every 0.1 µm for 11 µm). Blue corresponds to DAPI-stained nucleus and yellow dots mark LAMP2-positive lysosomes. (G) U2OS cells were treated with ConcA for 24 h, fixed and prepared for TEM. Images show toroidal nucleus surrounded by the nuclear envelope. Abbreviations: NE: nuclear envelope, N: nucleus, Cyt: cytosol, AV: autophagic vesicles. Scale bars: as indicated. (H) Analysis of live imaging experiment of cycling H2B-GFP U2OS cells for 24 h every 9 min. The number of mitotic cells with detectable mitotic errors (misaligned chromosomes or chromosomal bridges) and toroidal nuclei per field were quantified. Linear regression was analyzed and Pearson’s coefficient (R) was calculated. (I) Analysis of the percentage of toroidal nucleus formed upon non-apparent mitotic error or after mitotic errors. Error bars represent S.D. of n = 295 mitosis. (J) U2OS cells were depleted for KIF11 for 48 h using silencing RNA or treated with monastrol 100 µM for 24 h. Quantification of toroidal nuclei was performed by detection of DAPI-stained nuclei. Error bars represent S.D. of n > 3 experiments (10 fields/experiment). (K) Samples from panel J were processed by western blot and KIF11 protein levels were analyzed for knockdown efficiency. ACTB was used as a loading control. (L) Table summarizing a screen for toroidal nuclei through various cell lines. Percentage of toroidal nuclei was analyzed in basal population and upon ConcA or monastrol treatments. (M) Representative images of toroidal nuclei in screened cell lines from panel K. Scale bar: 5 µm. Panels I and J statistical significance is represented as: * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant
Lysosome disruption induces the formation of toroidal nuclei
The presence of toroidal nuclei in interphase cells facilitates the analysis of mitotic impairment in whole-cell populations, favoring the toroidal nucleus as a powerful tool for quantitative analysis of chromosomal instability. Here, we aimed to screen for lysosome-specific stresses using toroidal nucleus as a biomarker for chromosomal instability. To this end, cells were treated with ConcA or depleted for KIF5B and toroidal nuclei frequency was quantified. Consistently, v-ATPase inhibition as well as blockage of lysosome transport led to a robust increase of toroidal nuclei population (Figure 4A and S4A). To discard ConcA-side effects not related to v-ATPase inhibition, we genetically or chemically inhibited lysosome acidification. Thus, cells were treated with CQ or depleted of the V0C v-ATPase subunit (siATP6V0C). In agreement, inhibition of lysosome acidification increased the formation of toroidal nucleus by 2.5- to 3-fold (Figure 4B and S4B). To validate treatment efficiency, both blockade of the autophagic flux and morphological analysis of lysosomes were assessed by western blot or immunofluorescence, respectively. Our results confirmed the expected accumulation of LC3-II protein levels and increase in lysosomal volume [39] (Figure 4C, 4D and S4A, S4B, respectively).
Figure 4.
Toroidal nucleus frequency increases upon impairment of lysosome trafficking and acidification capacity. (A) U2OS cells were treated with ConcA (10 nM) for 24 h or depleted for KIF5B for 48 h using silencing RNA. Error bars represent S.D. of n > 5 experiments. (B) U2OS cells were treated with CQ (10 µM) or depleted for the V0C subunit of the v-ATPase (siATP6V0C) for 48 h. Error bars represent S.D. of n > 3 experiments. (C) Western blot analysis of the indicated proteins to show efficiency of the treatments used in panel B. ACTB was used as a loading control. (D) Quantitative real-time PCR to analyze the efficiency of siATP6V0C. (E) U2OS cells were depleted for BORC-associated proteins PLEKHM2 (siPLEKMH2) or ARL8B (siARL8B) using silencing RNA for 48 h. Error bars represent S.D. of n > 3 experiments. (F) U2OS cells were transfected with KIF5B silencing RNA and/or with KIF5A-GFP overexpression plasmid. Error bars represent S.D. of n > 3 experiments. (G) U2OS cells were depleted for KIF5B or PLEKHM2 and the next day treated or not with ConcA for 24 h. Error bars represent S.D of n > 3 experiments. In panels A-B, and D-G nuclei were stained with DAPI for detection and quantification of toroidal nuclei compared to total number of cells. * represents the statistical significance of single treatment effect compared to control, while # represents the effects of the second treatment over control. * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant, # p < 0.05 and ## p < 0.005, ### p < 0.001
Both ConcA and CQ increased toroidal nucleus formation, but their kinetics differed (Fig. S4C). Indeed, ConcA treatment acted faster and produced a peak effect at 24 h, while CQ produced a similar effect after 48 h, and further increased at 72 h (Fig. S4C). We further asked whether defects in BORC-dependent lysosome trafficking would also induce the formation of toroidal nuclei. Cells genetically depleted of BORC-associated proteins ARL8B or PLEKHM2 also showed a significant increase in the population of toroidal nuclei (2.3- and 4.1-fold, respectively) confirming the importance of lysosomal trafficking for correct mitotic progression (Figure 4E). Depletion efficacy was corroborated by the perinuclear clustering of lysosomes (Fig. S4D) as well as by significant decrease of protein or mRNA levels (Fig. S2I). Additionally, we examined the specificity of the motor function of KIF5B in the formation of toroidal nucleus by complementing control or KIF5B-depleted cells with the neuronal form KIF5A, which resulted in a rescue of normal toroidal nucleus frequency (Figure 4F). Interestingly, depletion of other motor proteins involved in lysosomal trafficking such as KIF3A, KIF2A or KIF1A also led to a significant increase in toroidal nuclei (Fig. S4E-G). Parallel to the delay in mitotic timing, we found that simultaneous disruption of lysosome acidification (ConcA) and trafficking (siKIF5B or siPLEKHM2) had an additive effect on toroidal nucleus formation compared to single treatments (Figure 4G). In all, our results confirm that both v-ATPase-dependent lysosome acidification and BORC-associated lysosomal trafficking are required to preserve mitotic integrity.Toroidal nucleus frequency increases upon impairment of lysosome trafficking and acidification capacity. (A) U2OS cells were treated with ConcA (10 nM) for 24 h or depleted for KIF5B for 48 h using silencing RNA. Error bars represent S.D. of n > 5 experiments. (B) U2OS cells were treated with CQ (10 µM) or depleted for the V0C subunit of the v-ATPase (siATP6V0C) for 48 h. Error bars represent S.D. of n > 3 experiments. (C) Western blot analysis of the indicated proteins to show efficiency of the treatments used in panel B. ACTB was used as a loading control. (D) Quantitative real-time PCR to analyze the efficiency of siATP6V0C. (E) U2OS cells were depleted for BORC-associated proteins PLEKHM2 (siPLEKMH2) or ARL8B (siARL8B) using silencing RNA for 48 h. Error bars represent S.D. of n > 3 experiments. (F) U2OS cells were transfected with KIF5B silencing RNA and/or with KIF5A-GFP overexpression plasmid. Error bars represent S.D. of n > 3 experiments. (G) U2OS cells were depleted for KIF5B or PLEKHM2 and the next day treated or not with ConcA for 24 h. Error bars represent S.D of n > 3 experiments. In panels A-B, and D-G nuclei were stained with DAPI for detection and quantification of toroidal nuclei compared to total number of cells. * represents the statistical significance of single treatment effect compared to control, while # represents the effects of the second treatment over control. * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant, # p < 0.05 and ## p < 0.005, ### p < 0.001Impairment of lysosome functionality does not appear to prevent mitotic cells from progressing into G1 phase but leads to CIN. In cells synchronized and released specifically in mitosis, ConcA and CQ similarly led to toroidal nuclei formation (2.6- and 2.7-fold increase, respectively) (Fig. S4H and S4I), indicating that the different kinetics of toroidal nucleus formation might be due to the effect of the drugs in other phases of the cell cycle. Interestingly, neither MG132 nor monastrol induced toroidal nuclei in these conditions (Fig. S4H and S4I), but rather imped cells from properly concluding cell division as previously demonstrated [40,41], thus limiting the generation of subsequent daughter cells harboring toroidal nuclei (Fig. S4I). We confirmed that inhibition of proteasome-dependent degradation by MG132 arrests cells at G2, as showed by a significant decrease of the mitotic index as well as an increase in G2/M phase by flow cytometry analysis (Fig. S4J and S4K). These results further suggest that lysosomes are not required to complete mitosis, but chromosomal instability is triggered when lysosomes are impaired.
Autophagy is a key player in maintaining mitosis fidelity
As we have detected the presence of autophagic vesicles in mitosis and being that lysosomes are the endpoint of autophagy, we analyzed the involvement of macroautophagy for faithful mitotic progression by scoring for toroidal nucleus frequency after macroautophagy inhibition. Genetic depletion of ATG5 (siATG5) induced a 5.11-fold increase in the proportion of toroidal nuclei (1.6-fold increase) (Figure 5A), while ConcA did not significantly affect the formation of toroidal nucleus in this setting (Figure 5A). In agreement with the correlation between mitotic errors occurrence and formation of toroidal nuclei, the inhibition of autophagy by ATG5 depletion provoked a significant increase in misaligned chromosomes and chromosome bridges (Figure 5B and 5C). Protein depletion efficiency was monitored by western blot (Fig. S5A). Chemical inhibition of autophagy by 3-methyladenine (3-MA), a PtdIns3 K inhibitor, also resulted in an increase in toroidal nuclei frequency together with an enhanced detection of chromosomal misalignment (Fig. S5B and S5C). As U2OS is a cancer cell line already susceptible to genomic instability and chromosome alterations [42], we used MEF to analyze the impact of defective autophagy on mitotic progression in a non-tumoral model. First, we validated ConcA efficiency and autophagic flux impairment by analyzing ATG5 and LC3 protein levels (Figure 5D). Then, we quantified the frequency of toroidal nuclei in WT (atg5+/+) and atg5 KO (atg5-/-) MEF. As expected, ConcA treatment significantly increased toroidal nuclei cell population in MEF WT (Fig. 5E, 5F, 3L and 3M). Parallel to the depletion of ATG5 in U2OS cells, MEF atg5-/- presented a significantly increased percentage of toroidal nuclei under normal growing conditions, supporting that basal autophagy prevents CIN. MEF atg5 were significantly more susceptible to chromosomal misalignment and chromosomal bridges compared to MEF WT (2.36- and 1.48-fold increase, respectively) (Figure 5G and 5H). Inhibition of v-ATPase-dependent lysosomal acidification by ConcA clearly increased chromosome misalignment and chromosomal bridges in control MEF WT (Figure 5G and 5H). Interestingly, cells lacking ATG5 showed a milder response to inhibition of lysosomal acidification regarding both mitotic errors and toroidal nucleus formation (Figure 5E, 5G and 5H), suggesting that macroautophagy is the main responsible process for those phenotypes, although macroautophagy-independent lysosome degradation could also occur, as suggested by the residual effects of ConcA in MEF atg5-/-. Altogether, our results establish the involvement of macroautophagy machinery in correct mitotic progression.
Figure 5.
Defective macroautophagy increases the occurrence of mitotic errors and toroidal nucleus formation. (A) U2OS cells were depleted for ATG5 for 48 h and treated or not with ConcA for 24 h. Error bars represent S.D. of n > 3 experiments. (B-C) Quantification of mitotic errors, including chromosome misalignment (B) and chromosome bridges (C) in U2OS cells control (siNT) or depleted for ATG5 (siATG5) for 48 h under normal growing condition (CTRL) or treated with ConcA 10 nM (24 h). Error bars represent S.D. of n = 4 experiments (>300 cells). (D) Validation of ATG5 depletion and ConcA efficacy in MEF WT and atg5-/- by western blot. ACTB was used as loading control. (E) MEF WT and atg5-/- were subjected or not to ConcA treatment for 24 h. DNA was labeled with DAPI and frequency of toroidal nuclei was quantified. Error bars represent S.D. of n = 3 experiments. (F) Representative image of normal and toroidal nucleus (yellow arrow) in MEF atg5-/- cells. Scale bar: 5 µm. (G-H) Quantification of mitotic errors, including chromosome misalignment (G) and chromosome bridges (H), respectively, in WT and atg5-/- MEF. Error bars represent S.D. of n = 5 experiments (>100 cells). Panels A-C, E and G-H, * represents the statistical significance of ConcA inhibitory effect compared to control, while # represents the effects of atg5 genetic depletion. * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant, # p < 0.05 and ## p < 0.005
Defective macroautophagy increases the occurrence of mitotic errors and toroidal nucleus formation. (A) U2OS cells were depleted for ATG5 for 48 h and treated or not with ConcA for 24 h. Error bars represent S.D. of n > 3 experiments. (B-C) Quantification of mitotic errors, including chromosome misalignment (B) and chromosome bridges (C) in U2OS cells control (siNT) or depleted for ATG5 (siATG5) for 48 h under normal growing condition (CTRL) or treated with ConcA 10 nM (24 h). Error bars represent S.D. of n = 4 experiments (>300 cells). (D) Validation of ATG5 depletion and ConcA efficacy in MEF WT and atg5-/- by western blot. ACTB was used as loading control. (E) MEF WT and atg5-/- were subjected or not to ConcA treatment for 24 h. DNA was labeled with DAPI and frequency of toroidal nuclei was quantified. Error bars represent S.D. of n = 3 experiments. (F) Representative image of normal and toroidal nucleus (yellow arrow) in MEF atg5-/- cells. Scale bar: 5 µm. (G-H) Quantification of mitotic errors, including chromosome misalignment (G) and chromosome bridges (H), respectively, in WT and atg5-/- MEF. Error bars represent S.D. of n = 5 experiments (>100 cells). Panels A-C, E and G-H, * represents the statistical significance of ConcA inhibitory effect compared to control, while # represents the effects of atg5 genetic depletion. * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant, # p < 0.05 and ## p < 0.005
Identification of novel lysosome substrates specifically during cell division
Based on the characterization of a remarkable role for lysosomes and autophagic vesicles in mitotic progression, we next aimed to identify novel substrates of the autophagic-lysosomal pathway specifically in mitosis by mass spectrometry analysis. Following synchronization of cells at G2, cells were released in control media or in media containing ConcA for 7 h. G1-enriched cell fractions were processed for mass spectrometry analysis. Drug efficacy was validated by LC3 and SQSTM1 accumulation in the three experimental replicates after ConcA treatment (Fig. S6A). Proteomic data analysis identified a total of 1749 peptides present in both ConcA and control fractions, while only 13 and 141 were uniquely detected in control and ConcA fractions, respectively (Figure 6A). Enrichment analysis validated 853 peptides being differently expressed (q-value<0.05) that were selected based on ± 1.2-fold change cut-off (Figure 6B). In accordance with its role in inhibiting lysosome-dependent degradation, ConcA significantly induced protein accumulation. The list of candidates was clustered into cellular functions using Reactome opensource database [43,44]. Reactome analysis highlighted that proteins accumulated after lysosome inhibition specifically during mitosis were mainly involved in cell cycle, vesicle-mediated transport or DNA repair (Fig. S6B and Table S1). As expected, SQSTM1 was significantly increased by 2.73-fold in the ConcA fraction compared to control (Figure 6B). Next, we focused on those candidates that clustered in functional annotations related to mitosis and cell cycle regulation based on gene ontology (GO) enrichment analysis (Table 1). A list of 20 proteins involved in mitotic cell cycle progress (GO: 1903047) were further studied to define the involvement of lysosomes in chromosome segregation (Table 1). Interestingly, among the principal enriched proteins, the two cofactors of the cohesin complex PDS5B (PDS5 cohesin associated factor B) and WAPL (WAPL cohesion release factor) were significantly increased by 4.78- and 1.64-fold, respectively (Figure 6B and Table 1). To validate the proteomic data, we isolated mitotic cells by shake-off after synchronization-release and evaluated protein levels in control and ConcA-treated cells. As expected, SQSTM1 and LC3-II autophagic proteins accumulated in ConcA-treated mitotic fraction (Figure 6C, 6D and S6C). Significant increase of both WAPL and PDS5B proteins occurred in mitotic cells upon acute impairment of lysosomal acidification capacity (Figure 6C and 6D), indicating that both PDS5B and WAPL are novel putative lysosomal substrates specifically during mitotic progression. To validate our findings in another cell line as well as in a model of autophagy impairment, we obtained shake-off fractions from MEF WT and atg5-/-. Mitotic fractions of non-synchronized MEF corroborated that PDS5B and WAPL significantly accumulated in MEF atg5-/- cells compared to MEF WT (Figure 6E, 6F and S6D). Thus, WAPL and PDS5B are potential lysosomal substrates degraded through the macroautophagy machinery.
Figure 6.
Identification of novel mitotic lysosomal substrates. (A) Venn diagram representing proteins detected by mass spectrometry of synchronized U2OS cells released in growing media (CTRL) or ConcA-containing media. (B) Volcano plot depicting fold-changes (FC) (log2) in protein abundances in cells treated with 10 nM ConcA. Three independent experiments were analyzed per condition. Dots denote the 1749 unique proteins detected in pre-filtered samples. Threshold at q-value < 0.05 depicts peptides significantly modified under experimental conditions. Blue dots represent peptides with FC < 0.8. Orange dots correspond to peptides presenting a FC > 1.2. Within these candidates, red dots indicate target proteins WAPL, SQSTM1 and PDS5B. (C) Western blot of synchronized U2OS mitotic cell fractions after mitotic cell enrichment by shake-off. Indicated proteins were analyzed. ACTB was used as loading control. (D) Quantification of WAPL, PDS5B, SQSTM1 and LC3-II band intensity in experimental conditions of panel D and normalized to ACTB protein level. Error bars represent S.D. of n = 3 experiments. (E) MEF WT and atg5-/- under normal growing conditions were subjected to shake-off. Mitotic enriched cell fractions were then analyzed by western blot and accumulation of WAPL and PDS5B was detected in MEF atg5-/-. ACTB was used as loading control. (F) Quantification of WAPL and PDS5B protein levels from panel F normalized to ACTB loading control. Error bars represent S.D. of n = 3 experiments. (G) Immunoprecipitation of exogenous WAPL-GFP in U2OS cells treated or not with 10 nM ConcA for 24 h. Cells only expressing exogenous GFP tag were used as negative control (H-I) Representative images of U2OS treated with ConcA (10 nM) for 24 h. Detection and localization of endogenous WAPL (H) or PDS5B (I) together with SQSTM1 were analyzed by immunofluorescence. Nuclei were stained with DAPI (blue). Scale bars: 10 µm. Magnification of SQSTM1-positive foci shows colocalization of WAPL with SQSTM1 (H) or PDS5B with SQSTM1 (I). Quantification of SQSTM1-containing foci colocalizing with WAPL (H, right panel) or PDS5B (I, right panel) in control and ConcA-treated cells for n ≥ 7 cells. In panels D, F, H-I, statistical significance is represented as: * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significant
Table 1.
Table summarizing the 20 candidates identified by mass spectrometry that are clustered in the Gene Ontology (GO) group of mitotic cell cycle progress (GO: 1903047)
Protein IDs
Protein names
Gene names
Fold- increase
Q00534
Cyclin-dependent kinase 6
CDK6
7.857
Q9NTI5
Sister chromatid cohesion protein PDS5 homolog B
PDS5B
4.780
Q15018
BRISC complex subunit Abro1
FAM175B
2.090
O00233
26 S proteasome non-ATPase regulatory subunit 9
PSMD9
1.911
P28070
Proteasome subunit beta type-4
PSMB4
1.831
Q7Z5K2
Wings apart-like protein homolog
WAPL
1.645
P50570
Dynamin-2
DNM2
1.644
P19784
Casein kinase II subunit alpha
CSNK2A2
1.547
P78406
mRNA export factor
RAE1
1.457
P62979
Ubiquitin-40S ribosomal protein S27a; Ubiquitin 40S ribosomal protein S27a
Table summarizing the 20 candidates identified by mass spectrometry that are clustered in the Gene Ontology (GO) group of mitotic cell cycle progress (GO: 1903047)To determine by which mechanism WAPL and PDS5B could be recruited and sent to degradation, U2OS cells were transfected with exogenous WAPL-GFP plasmid and treated or not with ConcA for 3 h after synchronization. Mitosis-enriched fractions were then subjected to GFP-immunoprecipitation. First, we validated the binding between WAPL and its well-described partner PDS5B [45] (Figure 6G). WAPL-GFP similarly interacted with PDS5B in control or ConcA-treated cells, suggesting that their interaction is maintained upon lysosomal inhibition. Interestingly, WAPL-GFP pulled down with the autophagic receptor protein SQSTM1 and this interaction significantly increased upon ConcA-treatment (Figure 6G). Interaction between SQSTM1 and WAPL and PDS5B was also supported by immunofluorescence analysis of the endogenous proteins in mitotic cells. Interestingly, bright foci containing SQSTM1 highly colocalized with both PDS5B and WAPL in dividing cells (Figure 6H and 6I). Furthermore, the number of colocalizing puncta was significantly increased upon ConcA treatment, supporting that WAPL and PDS5B are degraded by the lysosomes during mitosis, potentially through SQSTM1-mediated targeted degradation.Identification of novel mitotic lysosomal substrates. (A) Venn diagram representing proteins detected by mass spectrometry of synchronized U2OS cells released in growing media (CTRL) or ConcA-containing media. (B) Volcano plot depicting fold-changes (FC) (log2) in protein abundances in cells treated with 10 nM ConcA. Three independent experiments were analyzed per condition. Dots denote the 1749 unique proteins detected in pre-filtered samples. Threshold at q-value < 0.05 depicts peptides significantly modified under experimental conditions. Blue dots represent peptides with FC < 0.8. Orange dots correspond to peptides presenting a FC > 1.2. Within these candidates, red dots indicate target proteins WAPL, SQSTM1 and PDS5B. (C) Western blot of synchronized U2OS mitotic cell fractions after mitotic cell enrichment by shake-off. Indicated proteins were analyzed. ACTB was used as loading control. (D) Quantification of WAPL, PDS5B, SQSTM1 and LC3-II band intensity in experimental conditions of panel D and normalized to ACTB protein level. Error bars represent S.D. of n = 3 experiments. (E) MEF WT and atg5-/- under normal growing conditions were subjected to shake-off. Mitotic enriched cell fractions were then analyzed by western blot and accumulation of WAPL and PDS5B was detected in MEF atg5-/-. ACTB was used as loading control. (F) Quantification of WAPL and PDS5B protein levels from panel F normalized to ACTB loading control. Error bars represent S.D. of n = 3 experiments. (G) Immunoprecipitation of exogenous WAPL-GFP in U2OS cells treated or not with 10 nM ConcA for 24 h. Cells only expressing exogenous GFP tag were used as negative control (H-I) Representative images of U2OS treated with ConcA (10 nM) for 24 h. Detection and localization of endogenous WAPL (H) or PDS5B (I) together with SQSTM1 were analyzed by immunofluorescence. Nuclei were stained with DAPI (blue). Scale bars: 10 µm. Magnification of SQSTM1-positive foci shows colocalization of WAPL with SQSTM1 (H) or PDS5B with SQSTM1 (I). Quantification of SQSTM1-containing foci colocalizing with WAPL (H, right panel) or PDS5B (I, right panel) in control and ConcA-treated cells for n ≥ 7 cells. In panels D, F, H-I, statistical significance is represented as: * p < 0.05, ** p < 0.005, *** p < 0.001, ns: non-significantIn all, our results shed light on a novel regulatory mechanism for accurate mitotic progression, depicting lysosomes as key players for correct chromosomal congression and faithful genetic transmission (Figure 7). In addition, we identified the toroidal nuclei as a read-out of mitotic defects in interphase cells, and as such, as a novel biomarker of genotoxicity for cancer research.
Figure 7.
Impairment of lysosomes in mitotic cells leads to CIN. Lysosomal function is required for the maintenance of correct cell division and faithful transmission of genetic material in the two daughter cells. Functional lysosomes degrade essential mitotic factors necessary for appropriate chromosome segregation. However, when lysosomes are dysfunctional either by impairment of their trafficking or acidification capacity, mitotic cells are prompt to accumulate mitotic errors, to generate progeny with toroidal nuclei and mitosis is delayed. These alterations are key features of CIN
Impairment of lysosomes in mitotic cells leads to CIN. Lysosomal function is required for the maintenance of correct cell division and faithful transmission of genetic material in the two daughter cells. Functional lysosomes degrade essential mitotic factors necessary for appropriate chromosome segregation. However, when lysosomes are dysfunctional either by impairment of their trafficking or acidification capacity, mitotic cells are prompt to accumulate mitotic errors, to generate progeny with toroidal nuclei and mitosis is delayed. These alterations are key features of CIN
Discussion
Faithful mitotic progression relies on autophagy and lysosomes
During mitosis, dramatic cellular rearrangement occurs to support proper chromosome segregation and productive partitioning of intracellular organelles. Many membranous compartments undergo massive spatiotemporal disruption [16] and scheduled protein degradation is required. While the role of UPS has been extensively studied, the implication of lysosomes and autophagy in cell division still remains elusive [17,22,23]. Although lysosome studies are mainly focused on interphase cells, endocytic vesicles (including lysosomes) were proposed to serve as a membrane source for plasma membrane extension and retraction during mitotic transition [14,15]. Recently, PCM1-driven selective degradation of centriolar satellites was shown to maintain centrosome function for correct mitotic progression [25], and lysosome leakage was proposed to allow correct chromosome segregation [46]. Here, our results agree with the persistence of a robust autophagic flux and lysosomal-dependent degradation during mitosis [23].Other publications demonstrated that initiation of autophagy is inhibited during mitosis, even under MTORC1 inactive state, due to CDK1-dependent phosphorylation of ULK1 [20], or due to WIPI2 degradation [19]. Our results clearly demonstrated that autophagosomes and lysosomes are acidified during mitotic progression. From the apparent contradiction of these results arises the concept that, while de novo autophagosome formation may be inhibited in mitosis, preexisting or precursor autophagic vesicles can still play a role in mitotic progression. The finding that under basal conditions MEF atg5-/- harbor a higher population of toroidal nuclei corroborates that autophagy is active and necessary for mitosis also in non-transformed cells. Interestingly, even in a context of macroautophagy impairment, such as in the case of ATG5 depletion, v-ATPase inhibition by ConcA treatment tends to increase the occurrence of mitotic errors and toroidal nucleus suggesting that other types of autophagy, such as microautophagy or chaperone-mediated autophagy (CMA), could also be active during mitosis to degrade other protein substrates. Among the identified lysosomal substrates in mitosis, SQSTM1, an autophagic receptor protein for ubiquitinated cargos, confirms an active macroautophagic flux and suggests a potential alternative route to the proteasome for the degradation of mitotic factors [47,48].To note, PCM1 was not detected in our proteomic analysis of mitotic cells, supporting that various selective autophagy processes might coexist and be timely regulated during mitotic progression. Recently, SQSTM1 emerged as a potential pivotal player in the crosstalk between UPS and selective autophagosome-lysosome degradation [49,50]. Based on SQSTM1 bifunctionality and ubiquitin-lysine linkages diversity, we speculate that a potential interconnection between the two main degradative pathways exists to correctly distribute genetic material.Control of sister chromatid cohesion during cell division is crucial for equal distribution of genetic material. The canonical evolutionary conserved cohesin complex is one of the main molecular entities involved in this process and consists of four subunits (SMC1, SMC3, RAD21 and STAG1/3) [51]. Currently, most research focuses on cohesin loading processes during replication and cohesin-dependent extrusion of chromatin loops for DNA-damage repair [52]. In mitosis, cohesin supports both mitotic entry and metaphase-to-anaphase transition. In prophase, cohesin complexes dissociate to allow chromatid condensation and separation. At that precise moment, cohesin complex disruption is triggered by WAPL and PDS5B along the chromatids arms [53,54]. WAPL-dependent dissociation at the centromeric region is inhibited by SGO (shugoshin) to prevent premature chromatin separation [55,56]. During metaphase-to-anaphase transition, chromosome dissociation at the centromeric region is regulated by APC/C-dependent PTTG1 (PTTG1 regulator of sister chromatid separation, securin) ubiquitination, leading to ESPL1 (extra spindle pole bodies like 1, separase) activation that cleaves RAD21 to culminate chromatid separation [57].Since lysosomes can degrade most biological material and, considering that in this study we identified more than 100 potential lysosomal protein substrates in mitotic cells, we favor the idea that the implication of lysosomes in cell division is a multifactorial process. Our finding that WAPL and PDS5B accumulate upon blockade of lysosomal acidification identifies them as potential lysosomal substrates specifically during mitosis. Our study reports for the first time the involvement of autophagy- and lysosomal-dependent degradation of cohesin cofactors. The identification of WAPL as a novel SQSTM1 interactor supports the model of selective degradation of WAPL and PDS5B by the lysosome during mitotic transition. However, additional studies are needed to better understand the interconnection between lysosome-dependent degradation and the regulation of chromatid cohesion during mitotic progression, as well as the precise mechanism by which WAPL is recognized by SQSTM1 during cell division, either through its ubiquitination or indirectly via other SQSTM1-interactors. Our findings are specially relevant in the context of cancer, as variations in PDS5B and WAPL expression correlate cohesin and chromosomal segregation defects with aneuploidy and cancer progression [53,58-61].
Toroidal nucleus, a new tool for genotoxicity screenings
The study of mitosis is challenging due to the velocity and architectural changes accompanying cell division. To escape these obstacles, most mitosis-focused studies take advantage of synchronization protocols. However, drugs used for cell synchronization, such as nocodazole, do not specifically target mitosis but rather essential cellular components like microtubules, thus altering organelles trafficking among other basic cellular functions. Currently, the only marker of defective mitosis detectable in non-mitotic cells is the micronucleus. Although micronuclei are a consequence of chromosome missegregation [62], they can be reabsorbed during subsequent cell divisions or destroyed by autophagy [63,64]. Therefore, complementary read-outs in interphase cells are needed for the analysis of mitosis impairment. Here, we show that toroidal nuclei form upon inexact mitosis and linearly correlate with the occurrence of mitotic errors.Inhibition of farnesylation was previously proposed to drive the formation of donut-shaped nuclei by affecting centrosome function [31]. Here, we demonstrate that toroidal nuclei do not uniquely form upon inhibition of protein farnesylation. Indeed, FTI did not increase toroidal nucleus population in U2OS, while mitotic stressors, such as inhibition of lysosomal function or monastrol treatment, systematically increased the frequency of toroidal nuclei in various cell lines. In addition, our results reveal that toroidal nuclei form prior to the reformation of the nuclear envelope, as it was also described for micronucleus [65].The fate of micronuclei is still uncertain and four possibilities are under examination: degradation, reincorporation into the nucleus, extrusion or persistence in the cytoplasm leading to apoptosis or chromothripsis [66]. We expect similarities for toroidal nuclei, but further studies are needed to decipher how cells cope with toroidal nuclei. We detected toroidal nuclei in several transformed and non-transformed cells, designating the presence of this structure as a conserved phenotype within most cell lines. However, the occurrence of toroidal nuclei likely depends on cell type specificities and/or genetic background. Variability in toroidal nucleus frequency might also correlate with basal autophagy levels, which are known to be cell-type-specific [67]. In conclusion, the detection of toroidal nuclei is a new tool for the study of impaired mitosis in genotoxicity screenings.Until now, the orchestrated degradation of mitotic factors has been mostly attributed to the UPS. Our data reveals an additional route in which active autophagy and lysosomes promote faithful genetic transmission. Given the promising results of lysosomotropic drugs for cancer treatment, our study opens an alternative line of research focusing on lysosomes modulation to exploit CIN for cancer therapy.
Materials and methods
Cell culture
U2OS, HeLa, A549, HCT116, RKO, LoVo, MCF7, BJ5ta, HFF and HEK293-T cell lines were obtained from American Type Culture Collection (HTB-96; CCL-2; CCL-185; CCL-247; CRL-2577; CCL-229; HTB-22; CRL-4001, SCRC-1041 and CRL-11268, respectively). Huh7 cells were purchased at JCRN Cell Bank (JCRB0403). MEF WT and atg5-/- were kindly provided by Dr. Boya (CIB, Spain). U2OS H2B-GFP cell line was kindly provided by Dr. Agell (University of Barcelona, Spain). SF-8628 were purchased from Millipore Sigma (SCC127 M). MC-PED17 cells were a gift from Dr. Daniels (Mayo Clinic, Rochester, MN, USA). SU-DIPG-XVII cells were a gift from Dr. Monje (Stanford University, Stanford, CA, USA). U2OS mCherry-LMNA and U2OS H2B-GFP LAMP1-RFP were generated in our laboratory by transient transfection of plasmids purchased in Addgene repository, LAMP1-GFP (34831; deposited by Esteban Dell’Angelica), LAMP1-mRFP-Flag (34611; deposited by David Sabatini) and mCherry-LMNA (55068; deposited by Michael Davidson). U2OS cell line stably expressing Tandem-LC3 reporter was also generated in our laboratory after transient transfection and further selection of plasmid shared by Dr. Boya. WAPL-GFP plasmid was kindly shared by Dr. Wang (Zhejiang University, China). Briefly, DNA transfection was performed following manufacturer’s instructions using Lipofectamine 2000 (Thermo Fisher Scientific, 11668019) in 1:5 opti-MEM:DMEM medium (Gibco, 31985070 and 41966052). Cells were selected using a fluorescence-activated cell sorter (MoFlo Atrios SORTER). Cells were grown in DMEM high glucose (Gibco, 41966052) (4 mM L-glutamine, 4.5 g/L glucose, 1 mM pyruvate) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific, A3382001). Cells were incubated at 37ºC, 5% CO2 and 90–95% of relative humidity. Specific experimental conditions are indicated in figure legends. All chemicals used in this study are reported in Table 2.
Table 2.
List of reagents used in this study
Reagents
Working Concentration
Company and Catalog Number
BSA
From 0.1% to 3.5%
Sigma-Aldrich, A2153
Concanamycin A
10 nM
Santa Cruz Biotechnology, SC-20211A
Chloroquine
10 μM
Sigma-Aldrich, C6628
E64d
10 μM
Enzo Life Sciences, BML-PI107-0001
EDTA
5 mM
Thermo Fisher Scientific, 15575020
FBS
10%
Thermo Fisher Scientific, A3382001
Glycine
10 mM
Sigma-Aldrich, G8898
L744832 (FTI)
10 μM
MERCK, 422720
Lys-C
1:50
Wako, 4548995075888
Monastrol
100 μM
Sigma-Aldrich, M8515
Nocodazole
1 μM
Sigma-Aldrich, M1404
NP40
0.1% to 1.6%
Sigma-Aldrich, 74385
MG132
10 μM
Sigma-Aldrich, M7449
Phosphatase inhibitor cocktails
1:100
Sigma-Aldrich, P5726 and P0044
Propidium Iodide
40 µg/mL
Sigma-Aldrich, S7109
Protease inhibitor cocktail
1:100
Sigma-Aldrich, P8340
RNAase A
20 µg/mL
Invitrogen, 12091039
RO3306
9 μM
Sigma-Aldrich, SML0569
Sequencing Grade Trypsin
1:25
Promega, V5111
Thymidine
25 μM
Sigma-Aldrich, T1895
List of reagents used in this study
Cell synchronization at G2
Cells were seeded the day before starting the synchronization in DMEM medium supplemented with FBS. Thymidine (Sigma-Aldrich, T1895) was added at a final concentration of 2 mM for 24 h to synchronize cells at late G1. After phosphate-buffered saline (PBS; Gibco, 10010056) washing, cells were released to S phase by adding complete DMEM for 2 h. Finally, RO3306 (CDK1 inhibitor; Sigma-Aldrich, SML0569) was added to cell culture medium at a final concentration of 9 μM for 12 h to arrest cells at late G2 (Fig. S1C). Experiments with synchronized cells were performed by releasing cells in complete DMEM with or without the corresponding drugs for the indicated times. For the obtention of shake-off fractions, synchronized cells were subjected to consecutive strokes to the dishes to detach specifically the mitotic cells while maintaining the integrity of the cell monolayer. See Table 2 for reagents specifications.
Silencing RNA transfections
siRNA transfections were performed following manufacturer’s instructions in Opti-MEM medium (Gibco, 31985070) using Lipofectamine RNA-iMAX (Thermo Fisher Scientific, 13778150). Unless otherwise indicated, transfections were performed for 48 h. siRNA sequences and concentrations used in these studies are listed in Table S2.
Cell cycle analysis
Cells were trypsinized, counted and placed on ice. 500,000 cells were centrifuged at 800 x g at 4ºC for 5 min and cell pellet was washed with ice-cold PBS, fixed with 70% ethanol and placed at −20ºC for at least 24 h. Cells were then washed with ice-cold FACS buffer (0.1% BSA [Sigma-Aldrich, A2153], 5 mM EDTA in PBS) and centrifuged for 5 min at 800 x g at 4ºC. Supernatant was discarded and the cell pellet was resuspended in propidium iodide (PI) staining solution (PBS, 0.1% NP40 [Sigma-Aldrich, 74385], 20 µg/mL RNAse A [Invitrogen, 12091039], 40 µg/mL PI [Sigma-Aldrich, S7109]). Cell suspension was transferred to a 5 mL tube with cell strainer cap (Corning, 352235) and maintained at room temperature protected from light for 15 min. Samples were acquired using FACS Canto System (BD Biosciences, USA) and analyzed with ModFit LT software (Verity Software House).
Protein extraction and western blot
Cells were washed twice with ice-cold PBS, scraped and lysed on Lysis Buffer (20 mM Tris-HCl, pH 8, 10 mM EDTA, 150 mM NaCl, 1% Triton X-100 [Sigma-Aldrich, T8787]) supplemented with 1:100 protease inhibitor cocktail (Sigma-Aldrich, P8340) and 1:100 phosphatase inhibitors cocktails 2 and 3 (Sigma-Aldrich, P5726 and P0044). Cell lysates were centrifuged at 13000 x g for 10 min at 4ºC. Protein concentration was analyzed using Pierce BCA Protein Assay kit (Thermo Fisher Scientific, 23225) following manufacturer’s instructions. Equal amounts of protein lysates were resuspended in Laemmli SDS-sample buffer and incubated at 95ºC for 5 min. Proteins were separated on SDS-PAGE and transferred to PVDF membranes (Millipore, GE10600121). Membranes were blocked with 5% nonfat dry milk (BioRad, 1706404) in Tris-buffered saline containing 0.1% Tween-20 (Thermo Fisher Scientific, 28352; TBS-T) for 1 h at room temperature. Incubation of primary antibodies was performed overnight at 4ºC in 5% nonfat dry milk or 3.5% BSA. After three washes in TBS-T, membranes were incubated for 1 h at room temperature with secondary antibodies (1:5000) diluted in 5% nonfat milk. Upon incubation, membranes were washed three times with TBS-T and protein detection was performed by using enhanced chemiluminescence kit (GE Healthcare, GERPN2232). Blots were scanned with iBright detection system (Thermo Fisher Scientific, CL1000). All the antibodies used in this study are reported with the corresponding working concentrations in Table 3.
Table 3.
List of primary and secondary antibodies used in this study
List of primary and secondary antibodies used in this study
Immunoprecipitation
U2OS cells transfected with WAPL-GFP expression vector or GFP-empty vector as negative control were washed twice with ice-cold PBS and cellular pellets were kept at −80ºC before lysis. Cellular pellet was lysed in ice-cold IP-RIPA buffer (100 mM Tris-HCl, pH 7.5, 300 mM KCl, 10 mM MgCl2, 2 mM EGTA, 20% glycerol [Sigma-Aldrich, G5516], 1.6% NP40 [Sigma-Aldrich, 74385]) supplemented with protease inhibitors (2X), phosphatase inhibitors cocktails (1X), 1 mM PMSF (Sigma-Aldrich, 78830) and 1 mM DTT (Roche, 10708984001). After 5 min incubation on ice, collected samples were mechanically lysed with cold syringe and centrifuged at 13000 x g for 5 min at 4ºC. Soluble fraction was subjected to BCA Pierce protein quantification. Proteins (1500 µg per sample) were separated for immunoprecipitation at 1 μg/μL concentration. For the immunoprecipitation, 30 μL of GFP-Trap beads (ChromoTek, gtma-10) were added to each lysate and incubated by rotation overnight at 4ºC. Immunoprecipitates were washed three times with IP-RIPA buffer. Immunoprecipitated proteins were denatured by the addition of 2X sample buffer followed by boiling for 10 min, resolved by 4%-20% Criterion TGX Gel (BIO-RAD, 567–1094) electrophoresis and analyzed by immunoblotting. 20 μg of the total lysate were loaded as input to control.
Quantitative real-time PCR
Total RNA was extracted using TRIzol (Invitrogen, 93289) following manufacturer’s instructions. 1 μg of total RNA was subjected to reverse transcription and resulting cDNA samples were used in PCR amplification using LightCycler 96 SYBR Green I Master Mix (Roche Molecular Systems). Primers to amplify PLEKHM2 (F: 5ʹ-TCTCGCTGTCGGTGAAGAAG-3ʹ R: 5ʹ- AGGTCTTGCAGTCCGTACAG-3ʹ), KIF3A (F: 5ʹ-TGGCTGCAAAGTCAGAGATGG-3ʹ R: 5ʹ- ATCTGAAGTCGAAGCTCCCG −3ʹ) and ATP6V0C (F: 5ʹ-TCTACAAGAGCTTCCTCCAGC-3ʹ R: 5ʹ- CACCTCGGCGAAGATGAGAA-3ʹ) were used. Gene expression was normalized to the endogenous ACTB/β-actin (F: 5ʹ-AATGTGGCCGAGGACTTTGATTGC-3ʹ R: 5ʹ-AGGATGGCAAGGGACTTCCTGTAA-3ʹ).
Immunofluorescence
Cells were grown as monolayers on coverslips and subjected to the indicated conditions. Cells were fixed with 4% paraformaldehyde for 10 min at room temperature. After 5 min washing with PBS, cells were permeabilized using 0.1% Triton X-100 in PBS for 10 min at room temperature. Next, cells were blocked with 1% BSA/0.01% Triton X-100 in PBS plus 10 mM glycine (Sigma-Aldrich, G8898) for 30 min at room temperature. Cells were incubated with primary antibodies for one hour at room temperature or overnight at 4ºC. Following a series of PBS washes, cells were incubated with secondary antibodies for 45 min at room temperature. After two washes of 5 min with PBS, coverslips were mounted using Vectashield Mounting Solution containing DAPI (Vector Laboratories, H-1200). All the antibodies used in this study are reported with the corresponding working concentrations in Table 3.
Vesicle acidification and detection assays in live cells
U2OS cells were seeded onto glass coverslips and subjected to the indicated conditions. Live cells were washed once with PBS and Magic Red (Immunochemistry Technologies, 938) and LysoSensor (Invitrogen, L7545) were added to cover the cell layer following manufacturer’s instructions. Cells were incubated for 20 min under experimental conditions at room temperature before image acquisition.U2OS cells stably expressing the reporter construct Tandem-LC3 (mRFP-GFP-LC3B) were seeded onto glass coverslips, treated with ConcA (10 nM) or CQ (10 μm) for 24 h and then fixed and mounted as previously explained. Autophagosomes are detected as yellow-positive vesicles (red + green) while red-only vesicles correspond to acidified autophagic vesicles (autolysosomes), as the pH-sensitive GFP fluorophore gets quenched in acidified vesicles.
Image acquisition and analysis
For detailed analysis, images acquisition was performed in Leica spectral confocal microscope TCS SP5 using a 63x N.A 1.4 objective and LAS AF software or Carl Zeiss LSM880 confocal microscope and Zeiss ZEN software (Oberkochen, Germany). Fluorophores were excited with Argon 488, DPSS 561, Diode 640 and Diode 405 lasers. Image analysis was performed using FIJI ImageJ software (NIH, USA).For toroidal nucleus and mitotic errors quantification, images were acquired using Nikon Epifluorescence microscope using a 40x dry objective. Image analysis was performed using Cell counter plugin from FIJI ImageJ software. Pearson’s correlation coefficient was calculated based on confocal images using FIJI ImageJ plugin Intensity Correlation Analysis. Mitotic lysosomes size and number were analyzed with FIJI ImageJ fixing particle size from 0.3 μm2 to infinity. The distribution of mitotic lysosomes was calculated with FIJI ImageJ plugin Radial Profile Angle as previously described [68].
3D reconstitution
Stacks of images acquired at optimal settings with Carl Zeiss LSM880 confocal microscope were processed with IMARIS Software (Bitplane, Zürich, Switzerland) for 3D image reconstruction and to generate in silico animations and images.
Live-cell time-lapse videos
For mitotic delay analysis, U2OS H2B-GFP cells were grown onto glass-bottom 8-well slides (IBIDI, 80827). After indicated treatments, medium was replaced by FluoroBrite medium (Gibco, A1896702) and live-cell imaging was performed on the Leica spectral confocal microscope TCS SP5. Images were taken every 6 min and 33 s for a total time of 24 h using the 63x glycerol objective.For lysosome trafficking analysis, U2OS cells stably expressing LAMP1-RFP and H2B-GFP were grown onto glass-bottom 8-well slides (IBIDI, 80827). After indicated treatments, medium was replaced by FluoroBrite medium (Gibco, A1896702) and live-cell imaging was performed on Carl Zeiss LSM880 confocal microscope. Images were taken every 5 min for a total time of 24 h using the 63x glycerol objective.For toroidal nucleus and nuclear lamina reformation assays, U2OS cells stably expressing H2B-GFP and mCherry-LMNA were grown onto bottom-glass 8 chambers slides (IBIDI, 80827). After addition of FluoroBrite with indicated treatments, mitotic cell division was analyzed on a Carl Zeiss LSM880 confocal microscope. For toroidal nucleus formation, images were taken every 93 s for 16 h using the 63x glycerol objective. For nuclear envelope reformation experiment, images were taken every 5 min for 16 h using the 63x glycerol objective.
Transmission electron microscopy (TEM)
U2OS cells with or without ConcA (10 nM) treatment for 24 h were fixed with glutaraldehyde 2.5% in sodium cacodylate trihydrate 0.1 M pH 7.2 for 2 h at 4ºC. After three washes with sodium cacodylate trihydrate 0.1 M of 15 min each, samples were incubated for 2 h with osmium tetroxide 1% in sodium cacodylate trihydrate 0.1 M at room temperature. Samples were washed three times for 15 min with sodium cacodylate trihydrate 0.1 M. Then, samples were processed through dehydration with ethanol 30% to 100% gradually. Samples were then embedded into resin epoxy. After sample orientation, polymerization occurred at 60ºC for 48 h. Samples were cut using ultramicrotome EM UC6 Leica, first in semithin of 250 nm and then ultrathin of 70 nm. Image acquisition was performed with TEM microscope JEOL JEM-1011. Images were analyzed and processed with FIJI ImageJ software (NIH, USA).
Mass Spectrometry
Three replicates of treated samples were processed for protein extraction in RIPA lysis buffer (Tris-HCl [pH 8; 50 mM], NaCl 150 mM, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). Protein concentration was determined and 50 μg of each sample was digested using a FASP (Filter-Aided Sample Preparation) approach. Briefly, proteins were reduced with dithiothreitol (10 mM; 60 min, 32ºC) and alkylated with iodoacetamide ([Sigma-Aldrich, A3221], 20 mM; 30 min at 25ºC in the dark). Samples were loaded onto an Amicon Ultra filter 10 kDa, 0.5 mL (Millipore, ACS501002) to remove interfering agents with 2 rounds of centrifugations/washes with 100 mM ammonium bicarbonate buffer (13,600 x g; 25 min at room temperature). Digestion was carried out in two steps: first, samples were digested (1:50 w sample/w enzyme) with Lys-C (Wako, 4548995075888) in 6 M urea buffer (Sigma-Aldrich, U5378) for 3 h at 35ºC. Then, the samples were diluted 10-fold with 100 mM ammonium bicarbonate buffer and digested with modified porcine trypsin (Promega, V5111) (1:25 w sample/w enzyme) for 16 h at 37ºC. The resulting peptide mixture was recovered by centrifuging the filter and later the filter was washed twice with 300 μL of 50 mM ammonium bicarbonate and once with 200 μL of 20% acetonitrile/50 mM ammonium bicarbonate (13,600 x g for 25 min at room temperature). All the fractions were pooled, and the final peptide mixture was acidified with formic acid. Finally, the final volume of the acidified peptide solution was reduced on a SpeedVac vacuum system (Thermo Fisher Scientific), and the peptide solution was desalinated with a C18 spin column (Thermo Fisher Scientific) following supplier’s indications.Samples were analyzed in a Proxeon 1,000 liquid chromatographer coupled to an Orbitrap Fusion Lumos (Thermo Fisher Scientific) mass spectrometer. Samples were re-suspended in 0.5% formic acid in water, and 2 μL (1 μg/μL) were injected for LC-MS/MS analysis. Peptides were trapped on an NTCC-360/75-3-123 LC column and separated using a C18 reverse-phase LC column-Easy Spray (Thermo Fisher Scientific). The gradient used for the elution of the peptides was 1% to 35% in 90 min followed by a gradient from 35% to 85% in 10 min with 250 nL/min flow rate. Eluted peptides were subjected to electrospray ionization in an emitter needle (PicoTipTM, New Objective, Scientific Instrument Services) with an applied voltage of 2,000 V. Peptide masses (m/z 300–1,700) were analyzed in data-dependent mode where a full scan MS was acquired on the Orbitrap with a resolution of 60,000 FWHM at 400 m/z. Up to the 10 most abundant peptides (minimum intensity of 500 counts) were selected from each MS scan and then fragmented using collision-induced dissociation (CID) in the linear ion trap using helium as collision gas with 38% normalized collision energy. The scan time settings were full MS at 250 ms and MSn at 120 ms. Generated raw data files were collected with Thermo Xcalibur (v.2.2) (Thermo Fisher Scientific). MaxQuant 1.6.1.0 Software (Department for Proteomics and Signal Transduction, Max-Planck Institute for Biochemistry) was used to search the raw data obtained in the MS analyses against a SwissProt/Uniprot human database with Andromeda Search engine (1.5.6.0). A target and decoy database were used to assess the false discovery rate (FDR). Trypsin was chosen as enzyme and a maximum of two miscleavages were allowed. Carbamidomethylation (C) was set as a fixed modification, whereas oxidation (M) and acetylation (N-terminal) were used as variable modifications. Searches were performed using a peptide tolerance of 7 ppm and a product ion tolerance of 0.5 Da. Resulting data files were filtered for FDR <1%. Statistical analysis was performed in Perseus 1.6.2.1 (Department for Proteomics and Signal Transduction, Max-Planck Institute for Biochemistry).
Statistical analysis
Data was analyzed by Excel or GraphPad Prism8 software. Results are presented as Mean ± S.D., for the indicated (n) independent experiments. Experimental data sets were compared by: (i) Two-sampled, two-tailed Student’s t-test for two experimental conditions sharing normal distribution and variance (ii) One-way ANOVA test for more than 2 conditions sharing normal distribution and variance. Multiple comparisons corrected using Bonferroni test (iii) Kruskal-Wallis test for more than 2 conditions and data without assuming normal distribution. Multiple comparisons were corrected using Dunn’s test.Click here for additional data file.
Authors: Eeva-Liisa Eskelinen; Alan R Prescott; Jennifer Cooper; Saskia M Brachmann; Lijun Wang; Xiuwen Tang; Jonathan M Backer; John M Lucocq Journal: Traffic Date: 2002-12 Impact factor: 6.215
Authors: Henning Hintzsche; Ulrike Hemmann; Albrecht Poth; Dietmar Utesch; Jasmin Lott; Helga Stopper Journal: Mutat Res Rev Mutat Res Date: 2017-02-13 Impact factor: 5.657
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391
Authors: Juan Hormazabal; Francisco Saavedra; Claudia Espinoza-Arratia; Nicolas W Martinez; Tatiana Cruces; Iván E Alfaro; Alejandra Loyola Journal: Nucleic Acids Res Date: 2022-02-28 Impact factor: 16.971